Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Daily News

Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE

Yael L. Maxwell

September 23, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

Todd Neale

March 04, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

Michael O'Riordan

January 30, 2024

News Daily News

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

Todd Neale

January 16, 2024

Advertisement

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

April 2024 Dispatch for the CV Team

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Risk Factor Control Worse in Women Than Men in ISCHEMIA Trial

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content